Patents Assigned to GlaxoSmithKline LLC
-
Patent number: 9340513Abstract: The present invention relates to a compound characterized by the following Formula I: or a pharmaceutically acceptable salt thereof, wherein X, Y, and Z are as described herein. Compounds of the present invention are useful for the treatment of HIV.Type: GrantFiled: December 14, 2012Date of Patent: May 17, 2016Assignee: GlaxoSmithKline LLCInventors: Nianhe Han, Brian Alvin Johns, Jun Tang
-
Patent number: 9326986Abstract: Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.Type: GrantFiled: September 29, 2009Date of Patent: May 3, 2016Assignee: GLAXOSMITHKLINE LLCInventors: Chi B. Vu, Christopher Oalmann, Robert B. Perni, Brian White
-
Publication number: 20160106835Abstract: A novel combination comprising a B-Raf inhibitor, particularly N-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide or a pharmaceutically acceptable salt thereof, the MEK inhibitor N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)6,8-dimethyl; -2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide, or a pharmaceutically acceptable salt or solvate thereof, and a PD-1 antagonist; pharmaceutical compositions comprising the same and methods of using such combinations and compositions in the treatment of conditions in which the inhibition of MEK and/or B-Raf and/or immune modulation through PD-1 is beneficial, e.g., cancer.Type: ApplicationFiled: May 28, 2014Publication date: April 21, 2016Applicants: MERCK SHARP & DOHME CORP., GLAXOSMITHKLINE LLCInventors: Axel Hoos, Keith W. Orford, Patrick Chun, Venkataraman Sriram, Elaine M. Pinheiro, Scot W. Ebbinghaus
-
Patent number: 9315487Abstract: Tetrahydroquinoline compounds pharmaceutical compositions containing such compounds and their use in therapy.Type: GrantFiled: May 2, 2012Date of Patent: April 19, 2016Assignee: GlaxoSmithKline LLCInventors: Dominique Amans, Emmanuel Hubert Demont, Katherine Louise Jones, Jonathan Thomas Seal, Ann Louise Walker
-
Patent number: 9272836Abstract: Aspects of the present invention are directed to a metered dose container that is transit proof. A container of the present invention may comprise a body having a vertical axis; a cap movable along the vertical axis of the body; a removable ring coupled to and between the moveable cap and the body, and a barrier, inside the body and coupled to the moveable cap. The barrier may define a loading chamber and separate the body into a storage chamber and a dispensing chamber. The barrier is adapted to be movable along the vertical axis of the body to form a transit position and a dispensing position.Type: GrantFiled: August 8, 2013Date of Patent: March 1, 2016Assignee: GlaxoSmithKline, LLCInventors: Ramesh Ramachandran, Amit Sabharwal, Sukhdev Singh Saini
-
Patent number: 9243003Abstract: The present invention is a process comprising contacting a compound of formula 6: or a pharmaceutically acceptable salt thereof; with a deprotecting reagent to form a compound of formula A: or a pharmaceutically acceptable salt thereof; where R is H or OR1; R1 and each R1? are protecting groups; R1? is H or OH, and n is 0, 1, 2, 3, 4 , or 5.Type: GrantFiled: April 6, 2011Date of Patent: January 26, 2016Assignee: GlaxoSmithKline LLCInventors: Jose J. Conde, John Anthony Kowalski, Matthew Allen Zajac
-
Publication number: 20160017343Abstract: The present invention relates to genetically modified host cells, in particular yeast cells, comprising at least one isolated polynucleotide encoding a Killer Expression protease (Kex2p) or a fragment and/or variant thereof which has at least one Kex2p functional activity and at least one isolated polynucleotide encoding a Protein Disulfide-Isomerase (Pdi1) or a fragment and/or variant thereof which has at least one Pdi functional activity.Type: ApplicationFiled: March 6, 2014Publication date: January 21, 2016Applicant: GLAXOSMITHKLINE LLCInventors: Yonghwan JIN, Yuan ZHU
-
Patent number: 9233962Abstract: The present invention relates to compounds of formula (I): wherein R1 is C1-6alkylamino, C1-6alkoxy, or C3-7cycloalkyloxy; m is an integer having a value of 3 to 6; n is an integer having a value of 0 to 4; and salts thereof are inducers of human interferon. Compounds which induce human interferon may be useful in the treatment of various disorders, for example the treatment of allergic diseases and other inflammatory conditions for example allergic rhinitis and asthma, the treatment of infectious diseases and cancer, and may also be useful as vaccine adjuvants.Type: GrantFiled: May 16, 2014Date of Patent: January 12, 2016Assignee: GlaxoSmithKline LLCInventors: Keith Biggadike, Diane Mary Coe, Xiao Qing Lewell, Charlotte Jane Mitchell, Stephen Allan Smith, Naimisha Trivedi
-
Patent number: 9227914Abstract: Novel calcilytic compounds and methods of using them are provided.Type: GrantFiled: March 6, 2015Date of Patent: January 5, 2016Assignee: GlaxoSmithKline, LLCInventors: Robert W. Marquis, Linda N. Casillas, Joshi M. Ramanjulu, James Francis Callahan
-
Patent number: 9221766Abstract: This invention relates to novel compounds which are inhibitors of acyl coenzyme A: diacylglycerol acyltransferase 1 (DGAT-1), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination with weight management therapies or other triglyceride lowering therapy for the prevention or treatment of diseases related to DGAT-1 dysfunction or where modulation of DGAT-1 activity may have therapeutic benefit including but not limited to obesity, obesity related disorders, genetic (Type 1, Type 5 hyperlipidemia) and acquired forms of hypertriglyceridemia or hyperlipoproteinemia-related disorders, caused by but not limited to lipodystrophy, hypothyroidism, medications (beta blockers, thiazides, estrogen, glucocorticoids, transplant) and other factors (pregnancy, alcohol intake), hyperlipoproteinemia, chylomicronemia, dyslipidemia, non-alcoholic steatohepatitis, diabetes, insulin resistance, metabolic syndrome, cardiovascular outcomes, angina, exceType: GrantFiled: November 8, 2013Date of Patent: December 29, 2015Assignee: GlaxoSmithKline LLCInventors: Mui Cheung, Raghuram S. Tangirala
-
Publication number: 20150352121Abstract: A novel combination comprising the PI3K-? inhibitor 2-methyl-1-{[2-methyl-3-(trifluoromethyl)phenyl]methyl}-6-(4-morpholinyl)-1H-benzimidazole-4-carboxylic acid, or a pharmaceutically acceptable salt thereof, with a B-Raf inhibitor, particularly N-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of using such combinations and compositions in the treatment of conditions in which the inhibition of PI3K-? and/or B-Raf is beneficial, eg. cancer.Type: ApplicationFiled: February 19, 2014Publication date: December 10, 2015Applicant: GLAXOSMITHKLINE LLCInventors: Kurtis Earl BACHMAN, Joel David GRESHOCK, Mary Ann HARDWICKE
-
Publication number: 20150322082Abstract: This invention relates to novel compounds which are inhibitors of acyl coenzyme A: diacylglycerol acyltransferase 1 (DGAT-1), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination with weight management therapies or other triglyceride lowering therapy for the prevention or treatment of diseases related to DGAT-1 dysfunction or where modulation of DGAT-1 activity may have therapeutic benefit including but not limited to obesity, obesity related disorders, genetic (Type 1, Type 5 hyperlipidemia) and acquired forms of hypertriglyceridemia or hyperlipoproteinemia-related disorders, caused by but not limited to lipodystrophy, hypothyroidism, medications (beta blockers, thiazides, estrogen, glucocorticoids, transplant) and other factors (pregnancy, alcohol intake), hyperlipoproteinemia, chylomicronemia, dyslipidemia, non-alcoholic steatohepatitis, diabetes, insulin resistance, metabolic syndrome, cardiovascular outcomes, angina, exceType: ApplicationFiled: November 22, 2013Publication date: November 12, 2015Applicant: GlaxoSmithKline LLCInventors: Mui CHEUNG, Raghuram S. TANGIRALA
-
Patent number: 9173872Abstract: Compounds of formula (I) and salts thereof: wherein R1 is n-C1-6alkyl or C1-2alkoxyC1-2alkyl-, R2 is halo, OH or C1-3alkyl, m is an integer having a value of 4, 5, 6 or 7, n is an integer having a value of 0, 1, 2 or 3, and p is an integer having a value of 0, 1 or 2, are inducers of human interferon. Compounds which induce human interferon may be useful in the treatment of various disorders, for example the treatment of allergic diseases and other inflammatory conditions, for example allergic rhinitis and asthma, infectious diseases and cancer, and may also be useful as vaccine adjuvants.Type: GrantFiled: August 22, 2013Date of Patent: November 3, 2015Assignee: GlaxoSmithKline LLCInventors: Diane Mary Coe, Stephen Allan Smith
-
Patent number: 9163052Abstract: The invention relates to crystalline forms of 5,6-dichloro-2-(isopropylamino)-1-?-L-ribofuranosyl-1H-benzimidazole, pharmaceutical compositions comprising the same, processes for preparing the same, and their use in medical therapy.Type: GrantFiled: January 25, 2011Date of Patent: October 20, 2015Assignee: GlaxoSmithKline LLCInventors: Bobby Neal Glover, Lian-Feng Huang, Robert William Lancaster, Stacey Todd Long, Michele Catherine Rizzolio, Eric Allen Schmitt, Barry Riddle Sickles
-
Patent number: 9163024Abstract: The present invention relates to a tris salt of 8-chloro-3-pentyl-3,7-dihydro-1H-purine-2,6-dione of Formula (A) or a pharmaceutically acceptable salt thereof: corresponding pharmaceutical formulations, manufacture processes and uses of the aforementioned compound in therapy, particularly in treatment of diseases where under-activation of the HM74A receptor contributes to the disease or where activation of the receptor will be beneficial.Type: GrantFiled: December 7, 2009Date of Patent: October 20, 2015Assignee: GlaxoSmithKline LLCInventors: Holly Esken, Beth Adams Norton
-
Patent number: 9156797Abstract: This invention relates to the use of benzimidazole derivatives for the modulation, notably the inhibition of the activity or function of the phosphoinositide 3? OH kinase family (hereinafter PI3 kinases), suitably, PI3K?, PI3K?, PI3K?, and/or PI3K?. Suitably, the present invention relates to the use of benzimidazoles in the treatment of one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries. More suitably, the present invention relates to PI3K? selective benzimidazoles compounds for treating cancer.Type: GrantFiled: May 15, 2015Date of Patent: October 13, 2015Assignee: GlaxoSmithKline LLCInventors: Junya Qu, Ralph A. Rivero, Robert Sanchez, Rosanna Tedesco
-
Publication number: 20150272950Abstract: The present invention relates to a method of treating cancer in a human and to pharmaceutical combinations useful in such treatment. In particular, the method relates to a cancer treatment method that includes administering 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide, or a pharmaceutically acceptable salt thereof, and N-{(1S)-2-amino-1-[(3,4-difluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-furancarboxamide, or a pharmaceutically acceptable salt thereof, to a human in need thereof.Type: ApplicationFiled: October 21, 2013Publication date: October 1, 2015Applicant: GLAXOSMITHKLINE LLCInventor: Rakesh Kumar
-
Publication number: 20150272952Abstract: The present invention relates to a method of treating cancer in a human and to pharmaceutical combinations useful in such treatment. In particular, the method relates to a cancer treatment method that includes administering N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine, or a pharmaceutically acceptable hydrate and/or salt thereof, and N-{(1S)-2-amino-1-[(3,4-difluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-furancarboxamide, or a pharmaceutically acceptable salt thereof, to a human in need thereof.Type: ApplicationFiled: October 21, 2013Publication date: October 1, 2015Applicant: GlaxoSmithkline LLCInventors: Tona M. Gilmer, Rakesh Kumar
-
Patent number: D744328Type: GrantFiled: February 7, 2013Date of Patent: December 1, 2015Assignee: GlaxoSmithKline, LLCInventors: Ramesh Ramachandran, Amit Sabherwal, Sukhdev Singh Saini
-
Patent number: D747478Type: GrantFiled: February 5, 2014Date of Patent: January 12, 2016Assignee: GlaxoSmithKline, LLCInventors: Jeffrey S. Brunner, Gustav R. Fenton, Snigdha Mishra